Humana Inc. reported solid results for the second quarter, with the Insurance segment's benefit ratio of 89.9% aligning with expected medical cost trends. The company's 2Q25 Adjusted EPS slightly exceeded expectations. Humana has improved its full-year 2025 outlook and remains focused on enhancing its Medicare Advantage $(MA)$ margin by delivering clinical excellence. The company is confident in the strong core fundamentals and growth prospects for MA and value-based care, emphasizing its commitment to effective competition and better outcomes for members and patients.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。